This, together with suppressing NFκB activity, makes CGs potentially suitable for the treatment of sterile inflammation, NASH, or airway inflammation complicating cystic fibrosis. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatohepatitis.